ClinicalTrials.gg
WithdrawnNCT03610932Updated Dec 13, 2019

Vitamin C & Exercise Induced Bronchoconstriction (EIB)

An interventional study of Vitamin C and Placebo in Exercise-induced Bronchospasm, sponsored by University of Kansas Medical Center. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-13.

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Basic science

Why this study was withdrawn
Recruitment
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this research is to assess the association between diet and pulmonary function during standardized EIB testing. Determine the effect of Vitamin C supplementation on airway inflammatory markers and bronchoconstriction after a standardized EIB test compared to usual diet and placebo control.

Read the detailed description

This study will use a double-blind, randomized, cross-over design with subjects serving as their own controls. This study will be conducted over a consecutive five-week period.

All subjects will be asked to discontinue taking their short- and long-acting beta-agonist medication 12 and 24 hours respectively prior to data collection. Also, all subjects will be asked to refrain from caffeine, physical activity, and NSAID use 24 hours prior to testing. In addition all subjects will be asked to abstain from taking any vitamin supplement during the course of the study.

02

Conditions studied

  • Exercise-induced Bronchospasm
03

In context

Asthma, Exercise-Induced

52 studies on the registry are indexed under Asthma, Exercise-Induced; 3 are open to participants now.

Browse Asthma, Exercise-Induced studies →

Lead sponsor

University of Kansas Medical Center is the lead sponsor of 492 studies on the registry; 110 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Student or student-athlete who has tested positive for EIB
  • Able to communicate in English

Exclusion criteria

Exclusion Criteria:

  • (FEV1) \< 70% of predicted, cardiac history,
  • Current respiratory infection
  • > 10 pack year history of smoking
  • Pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Vitamin C

    Participants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.

    Dietary Supplement: Vitamin C

  • Active comparator
    Placebo

    Participants will ingest a matched capsule for size and color to the Vitamin C supplement.

    Other: Placebo

Interventions

  • Dietary supplementVitamin C

    Taken as 3 500mg capsules.

  • OtherPlacebo

    Taken as 3 500mg capsules.

06

What researchers measure

Primary outcomes

  1. Change in airway inflammatory biomarkers

    Urinary concentrations of cysteine leukotrienes (LTC4-LTE4), prostaglandin (9α,11β-PGF2), and creatinine will be measured.

    Time frame: Change from Baseline to End of Week 5

Secondary outcomes

  1. Change in quality of life: asthma quality of life questionnaire (AQLQ)

    Asthma specific quality of life will be measured by the validated asthma quality of life questionnaire (AQLQ). The AQLQ includes 32 separate responses within 4 domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). Each response option is based on a 7-point scale, where 1 represents maximal impairment and 7 indicates no impairment. Scores for the four domains and overall score are computed as averages of the item scores. The minimal important difference for overall and each domain, has been determined to be a change in score of 0.5 per item.

    Time frame: Change from Baseline to End of Week 5

  2. Dietary Intake Questionnaire

    Baseline dietary intake will be assessed by the National Cancer Institute's Diet Health Questionnaire II (DHQ II). It consists of 134 food items and 8 dietary supplement questions. It calculates the Healthy Eating Index (HEI) that is a measure of diet quality. Scores range from 0 to 100. The higher the score the healthier the diet.

    Time frame: Change from Baseline to End of Week 5

  3. Cardiorespiratory Fitness

    Cardiorespiratory fitness will be assessed during the EIB test by an integrated metabolic measurement system that will be used for measurement of oxygen consumption. The metabolic cart will be set to produce a 15-second average of the data collected during gas analyses for all tests.

    Time frame: Baseline

  4. Pulmonary function testing

    The outcome will measure the change in the first second of forced expiration (FEV1).

    Time frame: Change from Baseline to End of Week 5

07

Study locations

1 site
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in May 2019, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2018
First posted
Aug 1, 2018
StartActual
Jul 1, 2018
Primary completionActual
May 3, 2019
CompletionActual
May 3, 2019
Last update
Dec 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03610932
Responsible party
Sponsor
First posted
Aug 1, 2018
Start date
Jul 1, 2018
Primary completion
May 3, 2019
Completion
May 3, 2019
Last update
Dec 13, 2019

Study contacts

Dave Burnett, PhD, RRT, AE-C
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion